Symbyax en es it fr

Categorie

Symbyax Les marques, Symbyax Analogs

Symbyax Les marques melange

  • No information avaliable
  • Symbyax Formule chimique

    C17H20N4S

    Symbyax RX lien

    http://www.rxlist.com/cgi/generic3/symbyax.htm

    Symbyax FDA fiche

    Symbyax FDA

    Symbyax msds (fiche de securite des materiaux)

    Symbyax Synthese de reference

    JK Chakrabarti et al., US. 5,229,382 (1991)

    Symbyax Poids moleculaire

    312.434 g/mol

    Symbyax Point de fusion

    195oC

    Symbyax H2O Solubilite

    Aucune information disponible

    Symbyax Etat

    Solid

    Symbyax LogP

    2.199

    Symbyax Formes pharmaceutiques

    Tablet (oral)

    Symbyax Indication

    Pour le traitement de la schizophrénie et la maniaco-dépression (trouble bipolaire).

    Symbyax Pharmacologie

    L'olanzapine, un antipsychotique atypique, est utilisé pour traiter les symptômes positifs et négatifs de la schizophrénie, la manie aiguë avec le trouble bipolaire, l'agitation et des symptômes psychotiques dans la démence. Futur utilisations peuvent inclure le traitement du trouble obsessionnel-compulsif et troubles graves du comportement dans l'autisme. Structurellement et pharmacologique similaire à la clozapine, l'olanzapine se lie à l'alpha (1), la dopamine, , L'histamine H1, muscariniques, et 2 de type sérotonine (5-HT2) récepteurs.

    Symbyax Absorption

    Eh bien absorbé, avec environ 40% de la dose métabolisée avant d'atteindre la circulation systémique.

    Symbyax Toxicite

    Aucune information disponible

    Symbyax Information pour les patients

    PATIENT INFORMATION

    Physicians are advised to discuss the following issues with patients for whom they prescribe
    olanzapine:

    Orthostatic Hypotension: Patients should be advised of the risk of orthostatic hypotension,
    especially during the period of initial dose titration and in association with the use of
    concomitant drugs that may potentiate the orthostatic effect of olanzapine, e.g., diazepam
    or alcohol.

    Interference with Cognitive and Motor Performance: Because olanzapine has the potential to
    impair judgment, thinking, or motor skills, patients should be cautioned about operating
    hazardous machinery, including automobiles, until they are reasonably certain that olanzapine
    therapy does not affect them adversely.

    Pregnancy: Patients should be advised to notify their physician if they become pregnant or
    intend to become pregnant during therapy with olanzapine.

    Nursing: Patients should be advised not to breast-feed an infant if they are taking olanzapine.

    Concomitant Medication: Patients should be advised to inform their physicians if they are taking,
    or plan to take, any prescription or over-the-counter drugs, since there is a potential for
    interactions.

    Alcohol: Patients should be advised to avoid alcohol while taking olanzapine.

    Heat Exposure and Dehydration: Patients should be advised regarding appropriate care in avoiding
    overheating and dehydration.

    Phenylketonurics: ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) contains phenylalanine
    (0.34, 0.45, 0.67, or 0.90 mg per 5, 10, 15, or 20mg tablet, respectively).

    Laboratory Tests

    Periodic assessment of transaminases is recommended in patients with significant hepatic disease.

    Symbyax Organismes affectes

    Les humains et autres mammifères